Skip to main content
SpringerLink
Log in

Cost-Effectiveness Analysis

Obstacles to Standardisation and its Use in Regulating Pharmaceuticals

  • Guest Editorial
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Cairns J. Discounting and health benefits: another perspective. Health Economics 1: 76–79, 1992

    Article  PubMed  CAS  Google Scholar 

  • Coyle D, Tolley K. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate? PharmacoEconomics 2: 153–162, 1992

    Article  PubMed  CAS  Google Scholar 

  • Commonwealth of Australia, Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisor)1 Committee: Including submissions involving economic analysis. Department of Health, Housing and Community Services, Canberra, 1990

  • Drummond MF. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Economics 1: 85–92, 1992a

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF. Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang? PharmacoEconomics 1 (Suppl. 1): 61–69, 1992b

    Article  Google Scholar 

  • Drummond MF. Economic evaluation of pharmaceuticals: science or marketing? PharmacoEconomics 1: 8–13, 1992c

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. International Journal of Technology Assessment in Health Care 7: 561–573, 1991

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF, Brandt A, Luce BR, Rovira J. Standardizing economic evaluation methodologies in health care. International Journal of Technology Assessment in Health Care 9: 26–36, 1993

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF, Stoddarl GL. Economic analysis and clinical trials. Controlled Clinical Trials 5: 115–28, 1984

    Article  PubMed  CAS  Google Scholar 

  • Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. Journal of the American Medical Association 263: 407–413, 1990

    Article  PubMed  CAS  Google Scholar 

  • Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. Journal of the American Medical Association 262: 2879–86, 1989

    Article  PubMed  CAS  Google Scholar 

  • Elixhauser A, Luce BR, Taylor W, Reblondo J. Cost-benefit and cost-effectiveness analysis from 1979 to 1990: a bibliography. Medical Care Supplement, in press, 1992

    Google Scholar 

  • Fanshel S, Bush J. A health status index and its application to health-services outcomes. Operations Research 18: 1021, 1970

    Article  Google Scholar 

  • Fox DM, Leichter HM. Rationing carc in Oregon: the new accountability. Health Affairs 10: 7–27, 1991

    Article  PubMed  CAS  Google Scholar 

  • Freund DA, Ditlus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1: 20–31, 1992

    Article  PubMed  CAS  Google Scholar 

  • Health Industry Manufacturers Association. A guide to cosl-effectiveness analysis for medical devices and diagnostic manufacturers. Washington, DC, 1985

  • Henry D. Economic analysis as an aid to subsidization decisions: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1: 54–67, 1992

    Article  PubMed  CAS  Google Scholar 

  • Heyse JF, Cook JR. A new measure of cost effectiveness in comparative clinical economic trials. Paper presented to the American Statistical Society, Boston, Massachusetts, August 1992

    Google Scholar 

  • Hillman AL, Eisenberg JM, Pauty MV, Bloom BS, Glick H, et al. Avoiding bias in the conduct and reporting of cost-cffccliveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991

    Article  PubMed  CAS  Google Scholar 

  • Johannesson M. Research notes: on the discounting orgaincd life-years in cost-effectiveness analysis. International Journal of Technology Assessment in Health Care 8: 359–364, 1992

    Article  PubMed  CAS  Google Scholar 

  • Kaplan NM. Pitfalls in the interpretation of pharmacoeconomic studies. PharmacoEconomics 1(5): 303–305, 1992

    Article  PubMed  CAS  Google Scholar 

  • Ministry of Health, Drug Programs Branch. Toronto, Ontario. Canada Guidelines for preparation of economic analysis, to be included in Submission to Drug Programs Branch for Listing in the Ontario Drug Benefit Formulary Comparative Drug Index, DRAFT, October 15, 1991

  • O’Brien BJ, Drummond MF, Labelle RJ. In search of power & significance: statistical issues arising in the marriage of economic appraisal & clinical trials. Paper presented to the 8th annual meeting of the International Society of Health Care Technology Assessment, Vancouver. June 1992

  • Office of Disease Prevention and Health Promotion, U.S. Public Health Service, Kamlet MS, A framework for cost-utility analysis of government health care programs, US Public Health Service. 1992

  • Office of Technology Assessment. The implications of cost-effectiveness analysis of medical technology. Congress of the United States. Washington, DC, September 1980

  • Parsonage M, Neuburger H. Discounting and health benefits. Health Economics 1: 71–79, 1992

    Article  PubMed  CAS  Google Scholar 

  • Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Medical Care (Supplement) 27: S217, March 1989

    Article  Google Scholar 

  • Pharmaceutical Manufacturers Association. Cost-effectiveness of pharmaceuticals. Report Series, Washington, DC. 1983

  • Revicki DA, Rothman M, Luce BR. Health-related quality of life assessment and the pharmaceutical industry. PharmacoEconomics 1: 394–408, 1992

    Article  PubMed  CAS  Google Scholar 

  • Revicki DA. Relationship between health utility and psychometric health status measures. Medical Care 30 (Suppl): MS274–MS282, 1992

    Article  Google Scholar 

  • Russell L. Is prevention better than cure? The Brookings Institution, Washington, DC, 1986

    Google Scholar 

  • Stason W, Weinstein M. Allocation of resources to manage hypertension. New England Journal of Medicine 296: 732–739, 1977

    Article  PubMed  CAS  Google Scholar 

  • Torrance GW. Measurement of health stale utilities for economic appraisal. Journal Health Economies 5: 1–30, 1986

    Article  CAS  Google Scholar 

  • Warner KE, Luce BR. Cost-benefit and cost-effectiveness analysis in health care: Principles, practice and potential. Health Administration Press, University of Michigan, 1982

    Google Scholar 

  • Weinstein MC, Stason W. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 296: 716, 1977

    Article  PubMed  CAS  Google Scholar 

  • Willems JS, Sanders CR, Riddiough MA, Bell JC. Cost-effectiveness of vaccination against pneumococcal pneumonia. New England Journal of Medicine 303: 553–559, 1980

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Battelle Medical Technology Assessment and Policy (MEDTAP) Research Center, 901 D Street SW, Suite 900, Washington, DC, 20024, USA

    Bryan R. Luce

Authors
  1. Bryan R. Luce
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Luce, B.R. Cost-Effectiveness Analysis. Pharmacoeconomics 3, 1–9 (1993). https://doi.org/10.2165/00019053-199303010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199303010-00001

Search

Navigation